Park Ha Biological Technology Co., Ltd.

AI-generated fair value estimate for this company.

Method: Discounted net-asset-value approach rather than a DCF, since FY2025 (year ended 10/31/2025) net loss of $24.36M was driven almost entirely by a $24.07M non-cash stock-based-compensation charge against revenue of only $2.52M. Total shareholders' equity of $3,994,855 at fiscal year-end, of which cash was $3,787,678, against total liabilities of $1,957,761 and no interest-bearing debt. Applied a 40% discount to book equity for PRC/VIE cash-repatriation risk and continuing heavy share dilution, giving adjusted NAV of about $2.40M divided by about 6.058M current shares outstanding = $0.40/share.

Reasoning: At about $2.5M revenue with a GAAP loss distorted by non-cash stock compensation, this company is too thin and distorted for a credible DCF, so a cash-backed book-value approach grounded in the audited balance sheet is the rigorous alternative.